Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis

NCT07622212 · tracked via the Priya Life Science China tracker

Sponsor

RenJi Hospital

Phase

Observational

Started

2024-01-01

Last updated

2026-06-03

Condition(s) studied

Deep Vein Thrombosis

Investigational drug(s) / intervention(s)

Percutaneous mechanical thrombectomy by ClotTriever SystemPercutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy

Percutaneous mechanical thrombectomy by ClotTriever System: The procedure is performed via the ipsilateral popliteal vein access or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using stent retriever devices. Available stent retriever devices include currently marketed options such as ClotTriever (INARI MEDICAL, USA). After thrombectomy, the thrombus removal efficacy is assessed by venography.

Percutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy: The procedure is performed via the ipsilateral calf deep vein access, the ipsilateral popliteal vein access, or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using mechanical aspiration thrombectomy devices. Available aspiration thrombectomy devices include currently marketed options such as the AngioJet thrombectomy catheter (Boston Scientific, USA) and the Acostream thrombectomy catheter (Acotec, China). After thrombectomy, the thrombus removal efficacy is assessed by venography.

Study summary

A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: 1. Aged between 18 and 85 years; 2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein; 3. Time from symptom onset to endovascular treatment ≤ 14 days; 4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy; 5. Patients sign the informed consent form. Exclusion Criteria: 1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years; 2. Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb; 3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc. 4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc. 5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc. 6. Concomitant severe renal insufficiency with creatinine clearance \< 30 ml/min; 7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc. 8. Concomitant severe anemia (hemoglobin \< 8.0 mg/dL) or platelet count \< 80,000/mL; 9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm; 10. Pregnant women; 11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \< 24 months 12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month; 13. Patients unwilling to participate in this trial.

Primary outcome measure(s)

Incidence of PTS — At 24 months
Assessed by the Villalta score

Trial sites (1)

Facility	City	Region	Status
Renji hospital	Shanghai	China	Recruiting

More RenJi Hospital trials in China

HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC Starting soon

Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment Recruiting

CD70-targeted immunoPET Imaging of Malignant Cancers Recruiting

Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis Recruiting

Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders Recruiting

Other trials for the same condition

Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis Recruiting

PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis Recruiting

Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb Recruiting

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07622212 on ClinicalTrials.gov ↗ ← All trials in China